Clinical trials: Skin Conditions
Morphea
Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.
- Trial name
- NCT03351114
- Testing
- Crisaborole
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
Atopic Dermatitis
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to <18 years weighing ≥40 kilograms) with moderate-to-severe atopic…
- Trial name
- ADore (NCT04250350)
- Testing
- Lebrikizumab
- Where
- 70 sites in United States, Australia and 2 more
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
CHRONIC SPONTANEOUS URTICARIA
Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment
Evaluate the proportion of patients with an urticaria control test [UCT] score of greater than or equal to 12 at Week 12.
- Trial name
- SUNRISE (NCT02550106)
- Testing
- OMALIZUMAB
- Where
- 29 sites in France
- Volunteers
- 136 people
- Sponsor
- Novartis Pharmaceuticals
HER2-positive Breast Cancer, Recurrent Breast Cancer
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
This phase II trial studies how well pertuzumab, trastuzumab, and paclitaxel albumin-stabilized nanoparticle formulation work in treating patients with human epidermal growth factor receptor (HER) 2-positive stage II-IV breast…
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer
- Trial name
- NCT01730833
- Testing
- pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- City of Hope Medical Center
Bacterial Infections, Diabetic Foot
Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.
The purpose of this study was to look at the safety and effectiveness of a once-daily dose of tigecycline compared to ertapenem for the treatment of diabetic foot infections. The co-primary efficacy endpoints were not met.
- Conditions
- Bacterial Infections, Diabetic Foot, Osteomyelitis
- Trial name
- NCT00366249
- Testing
- Tigecycline, Ertapenem
- Where
- 211 sites in United States, Argentina and 37 more
- Volunteers
- 1,061 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Breast Cancer, Neurotoxicity
EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
RATIONALE: Chemotherapy may cause memory loss, attention loss, and other problems that make it difficult for patients to think clearly. EGb761 may help maintain mental clarity in patients undergoing chemotherapy.
- Trial name
- NCT00046891
- Testing
- Ginkgo Biloba
- Where
- 175 sites in United States
- Volunteers
- 226 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Locally Recurrent/Metastatic Triple Negative Breast Cancer
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
The study is being done to find out if the results of a pre-treatment biopsy can predict response to cisplatin and radiation treatment for patients with metastatic or recurrent triple negative breast cancer.
- Trial name
- NCT02422498
- Testing
- external beam radiation therapy, cisplatin, Biopsy of Target Tumor
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chemotherapy-induced Neutropenia
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastimt a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day.
- Trial name
- NCT01569087
- Testing
- empegfilrastim, filgrastim
- Where
- 5 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Biocad
Breast Cancer
Comparison of the Philips MicroDose Tomosynthesis System to 2D Digital Mammography
The primary objective of this study is to compare the safety and clinical performance of the Philips MicroDose Tomosynthesis system images and images from FFDM systems.
- Trial name
- NCT02615509
- Testing
- Imaging on experimental tomo device
- Where
- United States
- Volunteers
- 347 people
- Sponsor
- Philips Digital Mammography Sweden AB
Hand-foot Skin Reaction, Rash
Sorafenib-induced Hand- Foot Skin Reaction Treatment
The purpose of this study is to evaluate treatments for a rash caused by sorafenib.
- Trial name
- NCT00667589
- Testing
- urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
HER2/Neu Positive, HLA-A2 Positive Cells Present
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
This phase I/II trial studies the side effects of vaccine therapy and to see how well it works in treating patients with stage IV major histocompatibility complex, class I, A2 antigen (HLA-A2) and human epidermal growth factor…
- Conditions
- HER2/Neu Positive, HLA-A2 Positive Cells Present, Stage IV Breast Cancer, Stage IV Ovarian Cancer
- Trial name
- NCT00194714
- Testing
- HER-2/neu Peptide Vaccine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential safe and effective treatment for…
- Trial name
- NCT04915950
- Testing
- Temanogrel
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Pfizer
Breast Cancer
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.
- Trial name
- NCT00482391
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
High-Risk Melanoma
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
This study will evaluate the immunization effects of a vaccine for patients who are at risk for recurrence of their skin cancer. That is, the risk of cancer is higher if melanoma has invaded deep into the skin or lymph nodes.
- Trial name
- NCT00273910
- Testing
- gp100:209-217 (210M), Montanide ISA-51, Imiquimod
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
The goal of this clinical research study is to learn if the vaccines, gp100(g209-2M), and MAGE-3, when given in combination with resiquimod (R848), can help to stimulate the immune system against melanoma.
- Trial name
- NCT00960752
- Testing
- gp100, R848 gel, MAGE-3
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Interstitial Pneumonitis, Polymyositis
Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus
The purpose of the study is to evaluate the efficacy and safety of the combination treatment of tacrolimus and corticosteroid in polymyositis/dermatomyositis patients with interstitial pneumonitis with comparison against…
- Conditions
- Interstitial Pneumonitis, Polymyositis, Dermatomyositis
- Trial name
- IMPPACT (NCT00504348)
- Testing
- Tacrolimus
- Where
- 11 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Tokyo Medical and Dental University
Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
This randomized phase II trial studies how well giving pembrolizumab with standard chemotherapy, tumor infiltrating lymphocytes (TIL), and aldesleukin works in treating patients with melanoma that has spread to other areas of the…
- Conditions
- Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Trial name
- NCT02500576
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Psoriasis, Cardiovascular Disease
MIcrovascular dysfuNction In Moderate-severe Psoriasis
Psoriasis, a common chronic inflammatory skin disease affecting approximately 2% of the population, is associated with increased cardiovascular (CV) risk.
- Trial name
- MINIMA (NCT04271540)
- Testing
- Tildrakizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Marcelo F. Di Carli, MD, FACC
Breast Cancer
Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)
The purpose of this research is to establish if a once a year dose of Zoledronic Acid is sufficient to suppress and maintain urine and serum bone density markers (NTx) and serum CTx within normal range at 12 months post-dosing in…
- Trial name
- CTIBL (NCT00712985)
- Testing
- Zometa
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Active Dermatomyositis
Safety and Efficacy of BAF312 in Dermatomyositis
This study investigated the dose response relationship for the efficacy and safety of BAF312 compared to placebo in active DM patients over a treatment period of 6+6 months and to determine the minimum dose required for a maximal…
- Trial name
- NCT02029274
- Testing
- BAF312
- Where
- 9 sites in United States, Czechia and 1 more
- Volunteers
- 17 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.